Company intelligence / Profile preview

EverImmune

Villejuif, Île-de-France, Franceeverimmune.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

EverImmune has initiated a Phase I clinical trial for its lead candidate Oncobax® AK in NSCLC and RCC patients. The therapy is designed as an oral adjuvant to immunotherapy, aiming to overcome primary resistance by modulating the gut microbiome. Early-stage results are pending; first patient was dosed in January 2023. The company also has preclinical programs targeting breast and colon cancers.

Therapeutic areas: Oncology
Modalities: Live Biotherapeutic Products (LBPs)Commensal bacteria-based therapeutics
Industry: Biotech

Drug pipeline

3 assets

Oncobax FH

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Biose Industrie — contract development and manufacturing organization partner for GMP production of live biotherapeutics including Oncobax® AM/AKONCOBIOME — participant in this EU-funded European consortium focused on the role of the microbiome in oncology research and drug development

Beyond the preview

Go deeper on EverImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EverImmune.

Explore the full profile